Novacea halts ASCENT-2 trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Novacea halts ASCENT-2 trial

SOUTH SAN FRANCISCO, California—Novacea, Inc has ended its phase III ASCENT-2 clinical trial of Asentar (DN-101), the company's investigational cancer therapy for the treatment of androgen-independent prostate cancer. The trial was halted due to an imbalance of deaths between the two treatment arms, as observed by the study's Data Safety Monitoring Board. The study was comparing the benefits of weekly Asentar, an oral, intermittent high dose of calcitriol, plus docetaxel (Taxotere) with the current standard of care. The company plans to fully analyze the data to attempt to understand the cause of the higher death rate in the Asentar/Taxotere treatment group.

Articles in this issue
Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets
Recent Videos
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Tanya B. Dorff, MD, on Results From Phase 1 CAR T-Cell Therapy mCRPC Trial
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Assessing the Benefit of CAR T-cell Therapies for mCRPC
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Determining Personal and Professional Work/Life Balance in GU Oncology
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Observing the Evolving Prostate Cancer Landscape and Hopes for the Future
Related Content
Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

New Partnership May Expand Use of Prostate Cancer AI Technology Platform

Russ Conroy
February 27th 2025
Article

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

Darolutamide/ADT Yields Consistent Outcomes Across HSPC Age Subgroups

Ben Saylor
February 18th 2025
Article

Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index

Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index

Tim Cortese
February 14th 2025
Article

Patients who did not receive fish oil experienced a Ki-67 index increase of 24% vs the 15% Ki-67 index decrease for patients with a low omega-6, high omega-3 diet who received fish oil.

The ARANOTE phase 3 trial showed darolutamide plus ADT improved outcomes in mHSPC regardless of disease volume.

Darolutamide/ADT Improves Outcomes in mHSPC Across Disease Volumes

Kyle Doherty
February 13th 2025
Article

The ARANOTE phase 3 trial showed darolutamide plus ADT improved outcomes in mHSPC regardless of disease volume.